Arcturus Therapeutics Holdings Inc. Stock News

Arcturus Therapeutics (NASDAQ:ARCT) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$1.69 and the consensus…

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

Citing data from its Phase 1/2 booster study for ARCT-154 and ARCT-165, Arcturus Therapeutics (ARCT) says that the companys self-amplifying mRNA vaccine candidates strongly

Arcturus Therapeutics <> said data from ARCT-154 and ARCT-165 booster trial showed neutralizing antibody responses to SARS-CoV-2 and several variants.Full cohort data from

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates

Related Stocks: BIIB , IKNA , ABBV , GLPG , SIBN , LUNG , ADGI , ZBH , HCA , ERAS , SGEN , CTKB , PRLD , NTRA , ANTM , AFIB , ABCL , DCPH , AUPH , ASND , TRIL , ARCT , ALXN , ALEC ,

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)s share price gapped up before the market opened on Thursday . The stock had previously closed at $42.65, but opened at $43.86. Arcturus Therapeutics shares last traded at $42.00, with a volume of 2,855 shares. ARCT has been the subject of a number of analyst reports. Barclays decreased their price []

Brokerages predict that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will report sales of $12.90 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Arcturus Therapeutics earnings, with the lowest sales estimate coming in at $1.50 million and the highest estimate coming in at $43.40 million. Arcturus Therapeutics reported sales []

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) was up 8.9% during trading on Friday . The stock traded as high as $46.88 and last traded at $46.83. Approximately 19,475 shares changed hands during trading, a decline of 98% from the average daily volume of 825,301 shares. The stock had previously closed at $43.00. Several research analysts have []

The biotech stock climbed more than $5 a share in early trading Thursday.

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying mRNA vaccine candidates for COVID-

Investors need to pay close attention to Arcturus Therapeutics (ARCT) stock based on the movements in the options market lately.

Equities research analysts expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) to report ($1.81) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Arcturus Therapeutics earnings, with estimates ranging from ($2.31) to ($0.80). Arcturus Therapeutics posted earnings of ($1.25) per share in the same quarter last year, which []

Brokerages expect that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will announce earnings per share (EPS) of ($1.81) for the current quarter, according to Zacks. Four analysts have made estimates for Arcturus Therapeutics earnings, with estimates ranging from ($2.31) to ($0.80). Arcturus Therapeutics reported earnings of ($1.25) per share in the same quarter last year, which indicates []